A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Active, not recruiting · Phase 3 · NCT06045689
Conditions: Myelodysplastic Syndromes
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 20
- Sites paid
- 19
- Planned or actual enrollment
- 106
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Luspatercept (drug)
- Dates
- Started 2023-10-05; completion 2027-09-29
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
From ClinicalTrials.gov, last updated 2026-06-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1.2M in research payments for this study in 2025 (24 payments).
Products named: Reblozyl
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Vu Q. Phan, MD Hematology & Oncology · Los Alamitos, CA
- Marin F. Xavier, MD Medical Oncology · San Diego, CA
- Amer Zeidan Hematology & Oncology · New Haven, CT
- Adewale A. Fawole, M.D. Medical Oncology · The Villages, FL
- Ivor J. Percent, M.D. Medical Oncology · Port Charlotte, FL
- Sangeetha Venugopal, MD Hematology & Oncology · Miami, FL
- Jesus D. Gonzalez Lugo, M.D. Hematology & Oncology · Westwood, KS
- Wederson M. Claudino, MD Medical Oncology · Paducah, KY
- Ahmad H. Mattour, M.D. Hematology · Detroit, MI
- Meagan A. Jacoby, MD Medical Oncology · Saint Louis, MO
- Bruce T. Hayward, DO Family Medicine · Dillon, MT
- Mohamad A. Cherry, MD Hematology & Oncology · Morristown, NJ
- Lewis R. Silverman, MD Medical Oncology · New York, NY
- Luke B. Fletcher, MD Hematology & Oncology · Eugene, OR
- Anna Koget, D.O. Hematology & Oncology · Pittsburgh, PA
- Adelba Torres-lopez, M.D. Hematology & Oncology · San Juan, PR
- Elham Abbasi-hafshejani, M.D. Hematology & Oncology · The Woodlands, TX
- Praveen K. Tumula, M.D Hematology & Oncology · Amarillo, TX
- Ravi Kishore Narra, M.D., Hematology & Oncology · Menomonee Falls, WI
- Bhavana Bhatnagar, D.O. Hematology & Oncology · Wheeling, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute, Llc $419,016
- Mount Sinai School of Medicine $135,201
- Oncology Associates of Oregon, PC $125,238
- Kumc Research Institute, Incorporated $89,087
- Medical College of Wisconsin, Incorporated $75,064
- Lee Daeyeol Mms $70,585
- Washington University $61,613
- Cancer and Blood Specialty Clinic $40,820
- Morristown Medical Center, NJ $38,429
- Allegheny-Singer Research Institute (asri) $34,886
- Henry Ford Health Hospital, MI $31,250
- Texas Onco Southwest Fort Worth $28,836
- Auxilio Mutuo Hospital, PR $25,000
- Wvu Research Office $23,275
- University of Miami $18,780
- Scripps Mercy Hospital, CA $14,850
- Bon Secours Mercy Health, Inc $6,406
- Bon Secours Mercy Health Inc $4,500
- North Houston Cancer Reserach PLLC $900
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.